ABOUT ECTICA TECHNOLOGIES
Ectica Technologies AG is a Swiss supplier of hydrogel-based tools and materials to the biopharmaceutical and life science industries for applications in drug discovery and bioresearch. Our patented 3DProSeed® technology combines the biological relevance of cell-based assays in hydrogels with the highest workflow integration level in drug discovery. Besides its own product line, Ectica Technologies engages in contract development and production of original equipment manufacturer (OEM) solutions, which can be customised in terms of hydrogel chemistry, product format, usage and branding.
Ectica Technologies is a spin-off company of the ETH Zurich and University of Zurich.
3DProSeed® Hydrogel Plate
Our 3DProSeed® microtiter plate combines the advantages of hydrogel-based cultures with the
simplicity and workflow integration of standard polystyrene cultureware.
Our plate contains pre-assembled synthetic hydrogels, delivered to you hydrated, ready for cell seeding.
Hydrogel-based cultures have never been so
simple to establish.
Ectica Technologies engages in contract research and development directed to the integration of the 3DProSeed technology in drug discovery programs.
We also engage in development and production of OEM hydrogel solutions, which can be customised in terms of hydrogel chemistry, product format, usage and branding.
We are proud to support the brightest scientists in their fight against cancer.
Sabine Galland, MD-PhD is a Research Fellow in Oncology at the CHUV in Lausanne-Switzerland and used the 3DProSeed hydrogel plate to study the effect of simvastin on three-dimensional co-cultures of mesenchymal stromal cells and primary tumor cells and the crosstalk between tumor cells and the stromal tumor microenvironment.
"The 3DProSeed plate was easy to handle, including cell culture establishment and maintenance. It allowed us to analyze cell morphology and adhesion, as well as cytokine production. We greatly appreciated our collaboration with Ectica Technologies and the technical support provided". Sabine Galland MD-PhD.
Dr. Galland's work was recently published in Cancer Letters.
Merck KGaA is using our 3DProSeed technology to develop complex co-cultures in 3D, to mimic the physiology of human cancers in vitro, leading to clinically relevant data early in the drug discovery stages.